[CAS NO. 432499-63-3] 4E2RCat
PRODUCTS SPECIFICATIONS [432499-63-3]
DESCRIPTION [432499-63-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 455.93 |
| Molecular Formula | C22H14ClNO4S2 |
| SMILES | O=C(O)C1=CC(C2=CC=C(/C=C(SC(N3CC4=CC=CC=C4)=S)/C3=O)O2)=CC=C1Cl |
2 Publications Citing Use of MCE
Summary
4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC 50 of 13.5 μM.
IC50 & Target
IC50: 13.5 μM (eIF4E-eIF4G) [1]
In Vitro
4E2RCat prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation. It significantly decreases human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers. 4E2RCat inhibits cap-dependent translation in a dose-dependent manner. 4E2RCat inhibits cap-dependent FF translation but not EMCV IRES-driven Ren translation. 4E2RCat inhibits coronavirus replication in a dose- and time-dependent manner [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
4E2RCat inhibits protein synthesis in vivo and it is not a consequence of increased cell death [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 23.33 mg/mL ( 51.17 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1933 mL | 10.9666 mL | 21.9332 mL |
| 5 mM | 0.4387 mL | 2.1933 mL | 4.3866 mL |
| 10 mM | 0.2193 mL | 1.0967 mL | 2.1933 mL |
-
1.